Congressman David Trone, Co-Chair of the 140-Member Bipartisan Mental Health and Substance Use Disorder Task Force, Releases Statement on FDA Approving Narcan for Over-the-Counter Use
FOR IMMEDIATE RELEASE
March 29, 2023
Contact: Sasha Galbreath, Sasha.Galbreath@mail.house.gov
Congressman David Trone, Co-Chair of the 140-Member Bipartisan Mental Health and Substance Use Disorder Task Force, Releases Statement on FDA Approving Narcan for Over-the-Counter Use
Co-Founder and Co-Chair of the Bipartisan Mental Health and Substance Use Disorder Task Force Rep. David Trone (D-MD) released the following statement on the FDA authorizing Narcan for over-the-counter use:
“Studies have shown that more than one in five fatal overdoses could be averted with naloxone if it was distributed to more people in our communities. I applaud the FDA’s decision to bolster access to Narcan. It follows the facts and will undoubtedly save thousands – if not millions – of lives over time. As this plan rolls out, I hope that drug manufacturers work in good faith with pharmacies and insurers to ensure that cost does not become a barrier to care. I’m committed to doing my part in Congress to do just that.”
Congressman Trone’s State Opioid Response Grant Authorization Act of 2021 (H.R.2379) will deliver $8.75 billion over five years to states and tribes to help fund harm reduction (Naloxone distribution), along with treatment and recovery services.
Trone was elected to the House of Representatives in November 2018 to serve the 6th District of Maryland, which includes all or part of Montgomery, Frederick, Washington, Allegany, and Garrett Counties. Trone serves on the Appropriations, Budget, and Joint Economic Committees. In Congress, Trone is fighting to make progress on issues that matter to Marylanders, including the mental health and addiction crises, criminal justice reform, and funding for medical research.
